"These promising initial findings demonstrate the technical feasibility of the PD-L1 circulating blood test as well as the possibility of identifying a meaningful, clinically relevant threshold for the assay. Consequently, Biodesix has combined with collaborators in its physician network, including FirstHealth Moore Regional Hospital and Pinehurst Medical Clinic, to validate the assay by analyzing prospectively collected, matched plasma and tissue samples from patients previously diagnosed with stage III or later NSCLC. The samples will be evaluated for PD-L1 in both tissue and plasma, and for the tumor cytokeratin biomarker in plasma.”